CytImmune is a global leader in the field of cancer nanomedicine. The company has more than 60 issued and pending patents for its colloidal gold nanotechnology in the United States, European Union, Japan and Canada. We have successfully completed a Phase I clinical trial of CYT-6091 — the first in a series of nanomedicines based on our Aurimune nanomedicine platform. For more information about Aurimune or CytImmune, please visit our website, http://cytimmune.com.
This website is intended to offer opinions and insights from CytImmune’s staff and others who have expertise in cancer treatment, research and public policy. Posts and statements are not intended to be used for investment purposes. Metaphors, analogies and simplifications may sometimes be used to convey complicated scientific subjects. We’ll do the best we can to offer honest, insightful opinions on topics relevant to cancer researchers, patients, media and other stakeholders in the cancer community.
Keep it clean and on topic. No trolls. No bullies. Other than that, we welcome questions and comments. We reserve the right to remove comments and block users who we feel are not contributing to a thoughtful, relevant discourse.